Determination of IGF-I, IGF-II, IGFBP-2, and IGFBP-3 levels in serum and plasma: Comparisons using the Bland-Altman method

Growth Hormone and IGF Research

Volumn 13, Issue 6, 2003, Pages 341-346

  Renehan, Andrew G ^a   Jones, Jenny ^b   O'Dwyer, Sarah T ^a   Shalet, Stephen M ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Bland Altman plots; IGF binding proteins; Insulin like growth factors

Indexed keywords

EDETIC ACID; HEPARIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER RISK; CONTROLLED STUDY; CORRELATION COEFFICIENT; GROWTH DISORDER; HORMONE DETERMINATION; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SERUM; STANDARDIZATION; STATISTICAL SIGNIFICANCE; VOLUNTEER;

EID: 0345602031     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1096-6374(03)00112-6     Document Type: Article

References (20)

1. A.G. Renehan, M. Zwahlen, C. Minder, S.T. O'Dwyer, S.M. Shalet, M. Egger, Insulin-like growth factor (IGF)-I, IGF binding protein-3 and cancer risk: a systematic review and meta-regression, Lancet (submitted).
2. P. Delafontaine, Insulin-like growth factor I and its binding proteins in the cardiovascular system, Cardiovasc. Res. 30 (1995) 825-834.
3. M.S. Sandhu, A.H. Heald, J.M. Gibson, J.K. Cruickshank, D.B. Dunger, N.J. Wareham, Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study, Lancet 359 (2002) 1740-1745.
4. P.M. Jehle, K. Schulten, W. Schulz, D.R. Jehle, S. Stracke, B. Manfras, et al., Serum levels of insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-1 to -6 and their relationship to bone metabolism in osteoporosis patients, Eur. J. Intern. Med. 14 (2003) 32-38.
5. S.M. Shalet, A. Toogood, A. Rahim, B.M. Brennan, The diagnosis of growth hormone deficiency in children and adults, Endocr. Rev. 19 (1998) 203-223.
6. S.R. Peacey, S.M. Shalet, Insulin-like growth factor 1 measurement in diagnosis and management of acromegaly, Ann. Clin. Biochem. 38 (2001) 297-303.
7. A.G. Renehan, J.E. Painter, D. O'Halloran, W.S. Atkin, C.S. Potter, S.T. O'Dwyer, et al., Circulating insulin-like growth factor II and colorectal adenomas, J. Clin. Endocrinol. Metab. 85 (2000) 3402-3408.
8. A.G. Renehan, J. Jones, C.S. Potten, S.M. Shalet, S.T. O'Dwyer, Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer, Br. J. Cancer 83 (2000) 1344-1350.
9. P. Cohen, D.M. Peehl, T.A. Stamey, K.F. Wilson, D.R. Clemmons, R.G. Rosenfeld, Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients, J. Clin. Endocrinol. Metab. 76 (1993) 1031-1035.
10. R. Kaaks, P. Toniolo, A. Akhmedkhanov, A. Lukanova, C. Biessy, H. Dechaud, et al., Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women, J. Natl. Cancer Inst. 92 (2000) 1592-1600.
11. S.E. Hankinson, W.C. Willett, G.A. Colditz, D.J. Hunter, D.S. Michaud, B. Deroo, et al., Circulating concentrations of insulin-like growth factor-I and risk of breast cancer, Lancet 351 (1998) 1393-1396.
12. M. Garcia-Closas, S.E. Hankinson, S. Ho, D.C. Malins, N.L. Polissar, S.N. Schaefer, et al., Factors critical to the design and execution of epidemiologic studies and description of an innovative technology to follow the progression from normal to cancer tissue, J. Natl. Cancer Inst. Monogr. (2000) 147-156.
13. J.M. Bland, D.G. Altman, Statistical methods for assessing agreement between two methods of clinical measurement, Lancet 1 (1986) 307-310.
14. D.J. Morrell, H. Dadi, J. More, A.M. Taylor, A. Dabestani, C.R. Buchanan, et al., A monoclonal antibody to human insulin-like growth factor-I: characterization, use in radioimmunoassay and effect on the biological activities of the growth factor, J. Mol. Endocrinol. 2 (1989) 201-206.
15. A.M. Taylor, D.B. Dunger, M.A. Preece, J.M. Holly, C.P. Smith, J.A. Wass, et al., The growth hormone independent insulin-like growth factor-I binding protein BP-28 is associated with serum insulin-like growth factor-I inhibitory bioactivity in adolescent insulin-dependent diabetics, Clin. Endocrinol. (Oxf.) 32 (1990) 229-239.
16. P. Seed, sgl59. Confidence intervals for correlations, Stata Tech. Bull. 10 (2001) 267-269.
17. P. Seed, sbe33. Comparing several methods of measuring the same quality, Stata Tech. Bull. 10 (2001) 73-82.
18. H. Yu, J. Mistry, M.J. Nicar, M.J. Khosravi, A. Diamandis, J. van Doorn, et al., Insulin-like growth factors (IGF-I, free IGF-I and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation, J. Clin. Lab. Anal. 13 (4) (1999) 166-172.
19. T. Arai, W. Busby Jr., D.R. Clemmons, Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix, Endocrinology 137 (1996) 4571-4575.
20. S.K. Durham, A. Suwanichkul, J.D. Hayes, A.C. Herington, D.R. Powell, P.G. Campbell, The heparin binding domain of insulin-like growth factor binding protein (IGFBP)-3 increases susceptibility of IGFBP-3 to proteolysis, Horm. Metab. Res. 31 (1999) 216-225.